Here are 1-3 brief analogies for eXoZymes (EXOZ):

• Ginkgo Bioworks for enzyme-based chemical production.

• Intel, but designing biological modules for chemical manufacturing.

• Amazon Web Services (AWS) for biological chemical creation.

Here are the major products of EXoZymes:

• SimplePath Platform: A proprietary platform that utilizes enzymes for the biocatalytic production of various chemicals.
• Pharmaceuticals: Chemicals developed for medicinal and therapeutic applications.
• Fuels: Chemicals produced for use as energy sources.
• Materials: Chemicals designed for manufacturing and industrial applications.
• Food Additives: Chemicals created to enhance or preserve food products.
• Novel Compounds: Newly synthesized chemical substances with potential for diverse applications.

Based on the provided company description, EXoZymes (symbol: EXOZ) operates as a synthetic biochemical company that develops a platform to produce chemicals for various industries, including pharmaceuticals, fuels, materials, food additives, and novel compounds.

This business model indicates that EXoZymes primarily sells its platform and produced chemicals to other companies (Business-to-Business or B2B) rather than to individual consumers.

However, the provided background information does not list the names of specific major customer companies or their symbols.

Michael Heltzen, Chief Executive Officer & President
Michael Heltzen has served as the Chief Executive Officer of eXoZymes Inc. since February 1, 2024, and additionally as President since February 17, 2025. A serial entrepreneur, he previously held the position of EVP Strategy at Paragraf Ltd. from May to October 2023. Prior to that, Heltzen was the CEO of Cardea Bio Inc. from January 2019 to May 2023 and CEO & Chairman of Nanosens Innovations Inc. from December 2018 to September 2019. He has also served as Chairman of the Board for EXO Incubator Inc. since 2015 and Blue SEQ Innovations Inc. since 2010.

Fouad Nawaz, Director of Finance/CFO
Fouad Nawaz serves as the Director of Finance/CFO for eXoZymes Inc., a position he has held since August 31, 2023.

Tyler Korman, PhD, Chief Scientific Officer
Tyler Korman is a co-founder of eXoZymes Inc. (formerly Invizyne Technologies) and was appointed Chief Scientific Officer effective November 13, 2025. He has been with the company since its inception, previously serving as Director of R&D and Vice President of Research.

Damien Perriman, Chief Commercial Officer
Damien Perriman was appointed Chief Commercial Officer of eXoZymes Inc. in a newly created role on April 2, 2025. He brings over two decades of experience in successfully commercializing biotechnologies across various markets. Before joining eXoZymes, Perriman held leading commercial roles at Genomatica (Geno) and Gevo, and also served as Chairman of the Board for the Danish biotechnology startup Cellugy.

Paul Opgenorth, PhD, Vice President of Development
Paul Opgenorth is a co-founder and the Vice President of Development at eXoZymes Inc. He has been elected to key roles within the BioMADE Governance Committees, contributing to the definition of a technical roadmap for developing and deploying cell-free enzyme pathways.

1. Going Concern and Financial Viability: eXoZymes faces a significant risk to its ability to continue as a going concern due to severe funding erosion, accelerating operational cash burn, and a limited cash runway. Management explicitly cited "substantial doubt about its ability to continue as a going concern" as of Q2 2025, with net cash used in operations soaring by 62% and only $5.10 million in cash remaining, providing a tight 10-month runway at the current burn rate. This situation is exacerbated by material weaknesses in internal controls over financial reporting, which undermine financial transparency and could impede future capital raises. The company is compelled to seek immediate financing or accelerate strategic partnerships to sustain operations.
2. Market Acceptance and Competition in Synthetic Biology: The company confronts uncertainty regarding the market acceptance of its new products and technologies. This is coupled with the potential for increased competition within the synthetic biology sector, which could challenge eXoZymes' market position. As a young company without a significant history in manufacturing, product development, or marketing, successful commercialization of its SimplePath platform and derived products heavily relies on overcoming these market entry and competitive challenges, often through strategic partnerships.
3. Intellectual Property Protection and Brand Dilution: eXoZymes faces a notable intellectual property risk due to its decision not to trademark the term "exozymes." This choice could lead to potential dilution of its brand and create competitive vulnerabilities, as other companies may freely use the terminology, thereby potentially eroding eXoZymes' competitive advantage in the biomanufacturing space.

EXoZymes (EXOZ), a synthetic biochemical company, leverages its SimplePath platform to produce a range of chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds through biocatalytic conversion. The addressable markets for their main products and services are substantial and span several global sectors.

The global **biocatalysis and biocatalyst market** is a direct addressable market for EXoZymes' technology. This market was valued at approximately USD 642.48 million in 2025 and is projected to grow to about USD 1.21 billion by 2035, with a compound annual growth rate (CAGR) of 6.50% from 2026 to 2035. Other estimates place the market size at USD 719.88 million in 2025, reaching over USD 1.31 billion by 2035 at a CAGR of 6.2%, or USD 739.3 million in 2025, reaching USD 1374.7 million by 2035 at a CAGR of 6.4%. The biocatalyst enzymes segment alone was valued at US$ 755.9 million in 2025 and is estimated to grow at a CAGR of 7.1% from 2025 to 2033.

As a synthetic biochemical company, EXoZymes also operates within the broader **synthetic biology market**. This global market is projected to expand significantly, from an estimated USD 23.88 billion in 2025 to USD 130.67 billion by 2035, demonstrating an impressive CAGR of 18.53%. Other forecasts suggest a growth from US$ 25.62 billion in 2025 to US$ 239.38 billion by 2035, with a CAGR of 25.04%, or from USD 25.6 billion in 2025 to USD 128.1 billion by 2035 at a 17.5% CAGR.

EXoZymes' platform produces chemicals for various industries, including:

• **Pharmaceuticals:** The global **pharmaceutical chemicals market** is a major area of focus. This market was estimated at USD 147.97 billion in 2025 and is anticipated to reach USD 244.05 billion by 2032, with a CAGR of 7.4% from 2025 to 2032. Other estimations include a market size of USD 147.86 billion in 2025, growing to USD 158.32 billion in 2026 at a CAGR of 7.1%, or a valuation of US$232.4 billion in 2024, projected to reach US$308.9 billion by 2030 with a CAGR of 4.9%. The North America region is a dominant player in this market, expected to hold 37.0% of the market share in 2025.
• **Food Additives:** The global **food additives market** was estimated at USD 120.5 billion in 2024 and is projected to reach USD 169.22 billion by 2030, growing at a CAGR of 5.9% from 2025 to 2030. Other sources estimate the market size at USD 123.98 billion in 2025, increasing to USD 195.66 billion by 2034 at a CAGR of 5.20%, or USD 129.21 billion in 2025, growing to USD 218.34 billion by 2034 at a CAGR of 6%. Asia Pacific holds the largest revenue share in this market.
• **Fuels (Renewable Chemicals/Biofuels and Fuel Additives):** The **energy chemicals market** as a whole is expected to grow from $132.88 billion in 2025 to $141.22 billion in 2026, at a CAGR of 6.3%. More specifically, the global **fuel additives market** is projected to grow from USD 9.56 billion in 2023 to USD 16.64 billion by 2033, reflecting a CAGR of 5.7%. North America holds the largest market share in fuel additives, accounting for 48.25% in 2025.
• **Materials and Specialty Chemicals:** While not explicitly defined as a separate product category for EXoZymes, their platform produces "materials." The broader **global chemicals and materials market** is estimated to be valued at USD 1,020 billion in 2026 and is expected to reach USD 1,675 billion by 2033, with a CAGR of 7.1%. The **specialty chemicals market**, a segment of the overall chemicals market and highly relevant to EXoZymes' offerings, was estimated at USD 885.4 billion in 2025 and is expected to grow to USD 1.2 trillion by 2035.
• **Novel Compounds / Natural Health Products / Pharmaceutical Analogs:** EXoZymes also focuses on high-value natural products and pharmaceutical analogs, including an over-the-counter natural product (NCT) and novel non-intoxicating cannabinoids. While specific market sizes for these exact "novel compounds" are not readily available in broad market reports, the company itself describes these as "billion-dollar markets" with compounds valued at $500-$5,000/kg for natural health products and $5,000-$500,000+/kg for pharmaceutical analogs.

EXoZymes (NASDAQ: EXOZ) is poised for future revenue growth over the next 2-3 years, driven by several key strategic initiatives centered around its proprietary SimplePath platform and AI-enhanced enzyme technology. The company, currently in a pre-revenue stage, aims to generate income through a capital-light commercialization model.

Here are 3-5 expected drivers of future revenue growth:

• Commercialization of proprietary compounds through strategic partnerships: EXoZymes intends to generate revenue by commercializing its unique biochemical compounds, such as N-trans-caffeoyltyramine (NCT) and santalene, via various deal structures. This includes forming spin-out companies, establishing joint ventures, and entering into licensing agreements with partners who will handle large-scale production and market distribution. This strategy allows EXoZymes to leverage external capital and infrastructure while maintaining control over its core technology.
• Expansion into high-value pharmaceutical and nutraceutical markets: The company has strategically sharpened its commercial focus on the pharmaceutical and high-value nutraceutical sectors. These markets are characterized by high margins, strong intellectual property protection, and significant demand, where EXoZymes' AI-enhanced, cell-free exozyme platform is expected to provide differentiated capabilities and long-term value.
• Advancement and optimization of the AI-enhanced SimplePath platform: Continuous improvement and expansion of the underlying AI-engineered exozyme technology platform are crucial for future revenue growth. This includes the development of new, high-value biosolutions and enhancing the efficiency, purity, and scalability of existing ones, which directly supports the commercialization efforts across target markets.
• Strategic collaborations to accelerate scale-up and market entry: EXoZymes is actively pursuing strategic partnerships and collaborations, such as being a core industry partner in an NSF-funded initiative. These alliances are vital for securing market access, obtaining necessary infrastructure, and co-investing in the scale-up and go-to-market strategies, thereby minimizing EXoZymes' capital expenditure and execution risk while accelerating commercialization.

Share Issuance

• eXoZymes (as Invizyne Technologies, Inc.) completed its initial public offering (IPO) on November 11, 2024, raising $15 million by offering 1,875,000 shares of common stock at $8.00 per share.
• In January 2026, eXoZymes filed a shelf registration to offer up to $50,000,000 of various securities, including common stock, in future offerings.
• As of January 23, 2026, the company had 8,400,258 shares of common stock issued.

Inbound Investments

• MDB Capital Holdings, LLC was the primary investor in Invizyne Technologies since its inception, owning 62.86% of the common stock before the IPO, and served as the sole book-runner for the IPO.
• In August 2025, eXoZymes was selected as a core industry partner in a $9 million NSF-funded initiative, securing a $3 million share to advance modular cell-free biomanufacturing and develop a production module for santalene.

Outbound Investments

• eXoZymes launched NCTx in Q1 2025 as its first fully owned subsidiary, dedicated to developing and commercializing its platform with the small molecule compound N-trans-caffeoyltyramine (NCT).
• The company is strategically building a portfolio of high-value business opportunities, including creating ownership stakes in companies, joint ventures, and licensing partnerships.
• A Joint Venture with Joint Venture (Invizyne Technologies / Neuractas Therapeutics) was established on June 1, 2022.

Capital Expenditures

• eXoZymes invested $13,000 in capital expenditures in Q3 2025, which represents a 73.7% decrease from the previous quarter, primarily funding long-term assets and infrastructure.
• The company's strategy involves a "capital-light commercialization framework," aiming to minimize capital expenditures and execution risk through co-investment by strategic partners in scale-up and go-to-market activities.
• Increased operating expenses in Q1 and Q2 2025 were mainly attributed to expanded research and development and leadership hires to foster long-term growth.